Clinical trials: Sleep Problem
Insomnia, Sleep Initiation and Maintenance Disorders
Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography
To evaluate the efficacy of zolpidem for adolescent insomniacs with polysomnography
- Trial name
- NCT00653562
- Testing
- zolpidem
- Where
- 4 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Astellas Pharma Inc
Obstructive Sleep Apnea
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
The purpose of this clinical trial is to demonstrate long-term safety and efficacy of the Inspire system. The Inspire Upper Airway Stimulation (UAS) therapy is intended to treat moderate-to-severe obstructive sleep apnea by…
- Trial name
- STAR (NCT01161420)
- Testing
- Inspire Upper Airway Stimulation System
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 929 people
- Sponsor
- Inspire Medical Systems, Inc.
Restless Legs Syndrome
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
The objectives of the Post Market Surveillance (PMS) study are to evaluate the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Rating Scale and Global Clinical…
- Trial name
- NCT00721279
- Testing
- Sifrol® (pramipexole dihydrochloride)
- Where
- 127 sites in Austria
- Volunteers
- 549 people
- Sponsor
- Boehringer Ingelheim
Sleep Apnea - Obstructive
A Study of the Sleepnet Elara APAP Device
The goal of this study is to evaluate the effectiveness of the Elara APAP device.
- Trial name
- NCT07559708
- Testing
- Sleepnet Elara Treatment
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sleepnet Corporation
Sleep Deprivation
Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss
This is a double-blind, single center, parallel group, placebo and active comparator, controlled study to characterize the wake promoting effects of single doses of SPD489 in healthy adult male undergoing acute sleep deprivation.
- Trial name
- NCT01096680
- Testing
- SPD489 20 mg, SPD489 50 mg, SPD489 70 mg
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Shire
Obstructive Sleep Apnea
Inspire® Upper Airway Stimulation (UAS) System German Post-Market Study
The purpose of this study is to obtain additional safety and efficacy data on the use of Inspire® therapy for the treatment of subjects with moderate to severe Obstructive Sleep Apnea.
- Trial name
- NCT02293746
- Testing
- Inspire® Upper Airway Stimulation (UAS) System
- Where
- 3 sites in Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Inspire Medical Systems, Inc.
Insomnia
Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations
This is a single-center, open-label, randomized crossover study being conducted in three cohorts of healthy adult subjects. Approximately 36 subjects will be randomized to one of three cohorts (approximately 12 subjects per…
- Trial name
- NCT01673880
- Testing
- E2006
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Parkinson's Disease
Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.
- Trial name
- PD (NCT01032486)
- Testing
- Rasagiline mesylate
- Volunteers
- 120 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Obstructive Sleep Apnea
Crossover Trial of AD109 in Obstructive Sleep Apnea
This is a randomized, 4-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of AD109 versus its individual components or placebo in patients with obstructive sleep apnea.
- Trial name
- NCT04580394
- Testing
- AD109, Atomoxetine, R-oxybutynin
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Apnimed
Sleep Disorders
Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers
The purpose of this study is to determine whether SB-649868 is safe, tolerable after repeated administrations in adult and elderly healthy volunteers. Pharmacokinetics and effects on cardiac function of repeated doses are studied
- Trial name
- NCT01030939
- Testing
- SB-649868
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sleep Disorder, Nightmare
Validation of the Sleep Assessment Algorithm in the Medical Application Nightly
The Nightly medical application prototype is a potential, non-invasive class I medical device. The application has the potential to combine both diagnostic and therapeutic procedures for sleep.
- Trial name
- NCT03532269
- Testing
- Nightly App
- Where
- Poland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- DreamJay Sp. z o. o.
Excessive Sleepiness
Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder
The primary objective of the study is to determine whether armodafinil treatment is more effective than placebo treatment in patients with excessive sleepiness associated with shift work disorder (SWD) by measuring improved…
- Trial name
- NCT01080807
- Testing
- Armodafinil
- Where
- 63 sites in United States
- Volunteers
- 385 people
- Sponsor
- Cephalon
Narcolepsy Type 2
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
- Trial name
- Vibrance-2 (NCT06555783)
- Testing
- ALKS 2680
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 93 people
- Sponsor
- Alkermes, Inc.
Insomnia
Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
This study will investigate whether the plasma concentration-time profile and pharmacokinetics (PK) of suvorexant (MK-4305) in participants with impaired renal function are similar to those observed in healthy participants; and…
- Trial name
- NCT01059851
- Testing
- Suvorexant
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Apnea, Obstructive
Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA.
The solution offered by the Genio System to treat OSA patients with CCC using bilateral HGNS has a favorable risk-benefit ratio, as demonstrated by evidence from 2 studies.
- Trial name
- ACCCESS (NCT05592002)
- Testing
- Genio System
- Where
- 16 sites in United States
- Volunteers
- 124 people
- Sponsor
- Nyxoah S.A.
Sleep Initiation and Maintenance Disorders, Primary Insomnia
A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients
The purpose of the study is to investigate the efficacy and safety of zolpidem modified release (MR) tablet using estazolam (Eurodin) as a comparative drug in patients with primary insomnia.
- Trial name
- NCT00956319
- Testing
- Zolpidem MR, Estazolam
- Where
- Taiwan
- Volunteers
- 42 people
- Sponsor
- Astellas Pharma Inc
Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA)…
- Conditions
- Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
- Trial name
- TRIUMPH-1 (NCT05929066)
- Testing
- Retatrutide
- Where
- 134 sites in United States, Australia and 10 more
- Volunteers
- 2,335 people
- Sponsor
- Eli Lilly and Company
Insomnia Disorder
Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder
The main purpose of this study is to assess efficacy and safety of YZJ-1139 in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
- Trial name
- NCT05525637
- Testing
- YZJ-1139 20mg, YZJ-1139 40mg
- Where
- 83 sites in China
- Volunteers
- 1,037 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Restless Legs Syndrome
Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients
To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 week open label or double blind extension.
- Trial name
- NCT00275457
- Testing
- pramipexole
- Where
- 34 sites in Austria, Germany and 3 more
- Volunteers
- 346 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants
The purpose of the study is to evaluate effect of JNJ-42847922 on sleep latency (latency to persistent sleep) in participants with major depressive disorder who are stably treated with selective serotonin reuptake…
- Trial name
- NCT02067299
- Testing
- JNJ-42847922
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Janssen Research & Development, LLC